<DOC>
	<DOCNO>NCT00799760</DOCNO>
	<brief_summary>In order prevent high mortality due hypothetic pandemic cause newly emerge influenza A virus , antiviral drug see essential requirement control initial influenza outbreaks.Two antiviral available treatment oseltamivir zanamivir . Emergence Oseltamivir resistance recently report . . It appear opportune assess efficacy safety biotherapy neuraminidase inhibitor , investigate randomize , placebo control , double blind study France , next winter season . This study conduct 300 centre primary care 900 adult virologically suspect influenza A infection . Individuals randomize 1 3 treatment group : oseltamivir +zanamivir , oseltamivir+placebo placebo +zanamivir.The primary judgment criterion proportion patient negative RT PCR negative nasal secretion Day 2 .</brief_summary>
	<brief_title>Evaluation Efficacity Safety Oseltamivir Zanamivir</brief_title>
	<detailed_description>In near future , pandemic cause newly emerge influenza A virus predict WHO . In order prevent high mortality due pandemic , antiviral drug see essential requirement control initial influenza outbreak . Zanamivir ( GSK ) Oseltamivir ( Roche ) stockpile French government set pre-pandemic plan . In France , Zanamivir Oseltamivir register prophylactic therapeutic use influenza A . Previous study show neuraminidase inhibitor ( oseltamivir zanamivir , base treatment ) associate short illness duration result significant decrease viral load nasal secretion . In Winter season 2007-2008 presence oseltamivir-resistant virus circulate community several European country mark contrast previous winter season , oseltamivir resistance detect &lt; 1 % circulating strain . Patients infected virus neuraminidases carry mutation , n't present unusual disease syndrome . Although zanamivir oseltamivir issue class , combination two neuraminidase inhibitor could reduce duration severity acute influenza incidence secondary complication , reduce spread influenza , frequency neuraminidase inhibitor mutation . An evaluation combination oseltamivir zanamivir versus zanamivir placebo versus oseltamivir associate placebo treatment virologically suspect influenza primary care investigate randomise double blind placebo control trial study France winter season 2008-2009 . Primary outcome measure : Evaluate viral efficacy 2 day biotherapy oseltamivir zanamivir versus zanamivir placebo versus oseltamivir associate placebo . Patients method : Randomised double blind , placebo control multicenter trial conduct influenza season 2008-2009 Arm 1 : oral oseltamivir 75mg twice daily + zanamivir 10 mg inhale mouth twice daily 5 day Arm 2 : oral oseltamivir 75mg twice daily+ placebo inhale mouth twice daily 5 day Arm 3 : oral placebo twice daily + zanamivir 10 mg inhale mouth twice daily 5 day . Schedule : D0 : rapid test diagnostic influenza A urine pregnancy test woman inclusion /randomisation initiation treatment D2 : nasal sample influenza RNA RTPCR D5 : End treatment D7 : medical evaluation ( follow evaluation ) D14 : nurse call ( clinical evaluation )</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Influenza season declare Subjects age &gt; 18 year present within 36h documented onset influenza illness Who fever &gt; 38Â°C present least follow respiratory symptom ( cough , sore throat , nasal symptom ) one follow constitutional symptom ( headache , myalgia , sweat chill fatigue ) positive rapid diagnostic test influenza A give write informed consent prior enrollment Patient examine inclusion able complete questionnaire . Influenza Vaccination 12 month prior begin study Patient unable use diskhaler Zanamivir Asthma , Chronic bronchitis , Woman positive urine pregnancy test Clearance creatinine &lt; 30 ml/min Chronic renal disease History depression , psychiatric disorder oseltamivir zanamivir hypersensibility patient treat oseltamivir zanamivir amantadine 14 day Non member social security CMU</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>influenza A</keyword>
	<keyword>neuraminidase inhibitor</keyword>
	<keyword>oseltamivir</keyword>
	<keyword>zanamivir</keyword>
	<keyword>treatment outcome</keyword>
	<keyword>resistance</keyword>
	<keyword>mutation</keyword>
	<keyword>combination therapy</keyword>
	<keyword>monotherapy</keyword>
	<keyword>pandemic</keyword>
	<keyword>primary care</keyword>
	<keyword>randomize controlled trial</keyword>
	<keyword>antiviral agent</keyword>
</DOC>